RxDoctor Payments Data

Stephen Clark, MD

Ophthalmology · Perrysburg, OHNPI 1134122948

Payments from drug & device makers

$1,807in general payments, 2019–2025

Across 39 payments — averaging $46.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$623
  • AbbVie$397
  • Bausch & Lomb Americas Inc.$135
  • Regeneron Healthcare Solutions, Inc.$125
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$115
  • Sight Sciences, Inc.$105
  • plus $308 from 11 others

What the payments were for

  • Travel & lodging$62334%
  • Food & beverage$1,12262%
  • Entertainment$623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,807 in reported general payments places this provider in the 55th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$412,123
Medicare patients
1,714
Services billed
4,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$49,567
LumiganBimatoprost73$33,095
VyzultaLatanoprostene Bunod62$29,015
RocklatanNetarsudil Mesylat/Latanoprost46$25,953
Latanoprost1,411$13,524
Prednisolone Acetate358$13,191
Cyclosporine18$11,936
Restasis MultidoseCyclosporine12$8,985
Timolol Maleate487$8,886
CombiganBrimonidine Tartrate/Timolol16$7,709
Travoprost24$7,056
Brimonidine Tartrate191$6,064
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat334$5,426
RhopressaNetarsudil Mesylate12$5,069
Bromfenac Sodium33$4,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$397$99,357146 claims
Bausch & Lomb Americas Inc.Vyzulta$135$29,01562 claims
AlconSimbrinza$20$2,38212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Perrysburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →